AU725494B2 - Slow-release pharmaceutical formulations containing mizolastin - Google Patents

Slow-release pharmaceutical formulations containing mizolastin Download PDF

Info

Publication number
AU725494B2
AU725494B2 AU19300/97A AU1930097A AU725494B2 AU 725494 B2 AU725494 B2 AU 725494B2 AU 19300/97 A AU19300/97 A AU 19300/97A AU 1930097 A AU1930097 A AU 1930097A AU 725494 B2 AU725494 B2 AU 725494B2
Authority
AU
Australia
Prior art keywords
mizolastine
sustained
release pharmaceutical
pharmaceutical formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU19300/97A
Other languages
English (en)
Other versions
AU1930097A (en
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU1930097A publication Critical patent/AU1930097A/en
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Amend patent request/document other than specification (104) Assignors: SYNTHELABO
Application granted granted Critical
Publication of AU725494B2 publication Critical patent/AU725494B2/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Request to Amend Deed and Register Assignors: SANOFI-SYNTHELABO
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU19300/97A 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastin Expired AU725494B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/02662 1996-03-04
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PCT/FR1997/000355 WO1997032584A1 (fr) 1996-03-04 1997-02-28 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (2)

Publication Number Publication Date
AU1930097A AU1930097A (en) 1997-09-22
AU725494B2 true AU725494B2 (en) 2000-10-12

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19300/97A Expired AU725494B2 (en) 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastin

Country Status (34)

Country Link
US (2) US6165507A (enEXAMPLES)
EP (1) EP0906101B1 (enEXAMPLES)
JP (2) JP2000512617A (enEXAMPLES)
KR (1) KR100369888B1 (enEXAMPLES)
CN (1) CN1112929C (enEXAMPLES)
AR (1) AR006082A1 (enEXAMPLES)
AT (1) ATE219365T1 (enEXAMPLES)
AU (1) AU725494B2 (enEXAMPLES)
BG (1) BG63451B1 (enEXAMPLES)
BR (1) BR9707827A (enEXAMPLES)
CA (1) CA2247405C (enEXAMPLES)
CO (1) CO4780020A1 (enEXAMPLES)
CY (1) CY2293B1 (enEXAMPLES)
CZ (1) CZ291418B6 (enEXAMPLES)
DE (1) DE69713505T2 (enEXAMPLES)
DK (1) DK0906101T3 (enEXAMPLES)
EE (1) EE03511B1 (enEXAMPLES)
ES (1) ES2177942T3 (enEXAMPLES)
FR (1) FR2745500B1 (enEXAMPLES)
HU (1) HU227472B1 (enEXAMPLES)
IL (1) IL126050A (enEXAMPLES)
IN (1) IN187739B (enEXAMPLES)
NO (1) NO315841B1 (enEXAMPLES)
NZ (1) NZ331947A (enEXAMPLES)
OA (1) OA10854A (enEXAMPLES)
PL (1) PL189813B1 (enEXAMPLES)
PT (1) PT906101E (enEXAMPLES)
RU (1) RU2173997C2 (enEXAMPLES)
SK (1) SK282112B6 (enEXAMPLES)
TR (1) TR199801574T2 (enEXAMPLES)
TW (1) TW491711B (enEXAMPLES)
UA (1) UA49004C2 (enEXAMPLES)
WO (1) WO1997032584A1 (enEXAMPLES)
ZA (1) ZA971830B (enEXAMPLES)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101564A (ja) * 1996-09-27 1998-04-21 Mitsubishi Chem Corp 鼻炎予防及び／又は治療剤
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
PT1322158E (pt) * 2000-10-02 2012-11-23 Usv Ltd Composições farmacêuticas de libertação prolongada contendo metformina e seu método de produção
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2518442A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
CN104784180A (zh) * 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261979A (ja) * 1985-09-11 1987-03-18 シンセラボ ベンズイミダゾ−ル誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
RU2015975C1 (ru) * 1992-02-13 1994-07-15 Пятигорский фармацевтический институт Производные 4-оксо-1,4-дигидропиримидина, обладающие антиаллергической и иммунотропной активностью
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261979A (ja) * 1985-09-11 1987-03-18 シンセラボ ベンズイミダゾ−ル誘導体
EP0217700A1 (fr) * 1985-09-11 1987-04-08 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP0906101A1 (fr) 1999-04-07
TW491711B (en) 2002-06-21
BR9707827A (pt) 1999-07-27
PL189813B1 (pl) 2005-09-30
JP2000512617A (ja) 2000-09-26
HUP9902458A3 (en) 2002-11-28
RU2173997C2 (ru) 2001-09-27
BG63451B1 (bg) 2002-02-28
OA10854A (fr) 2003-02-05
AU1930097A (en) 1997-09-22
CN1212624A (zh) 1999-03-31
CA2247405A1 (en) 1997-09-12
TR199801574T2 (xx) 1998-11-23
EE9800275A (et) 1999-02-15
CY2293B1 (en) 2003-07-04
KR100369888B1 (ko) 2003-05-17
US20050202089A1 (en) 2005-09-15
PL328763A1 (en) 1999-02-15
US6165507A (en) 2000-12-26
CA2247405C (en) 2004-04-20
CN1112929C (zh) 2003-07-02
CZ291418B6 (cs) 2003-03-12
HK1017999A1 (en) 1999-12-10
CZ279198A3 (cs) 1999-01-13
WO1997032584A1 (fr) 1997-09-12
PT906101E (pt) 2002-09-30
FR2745500A1 (fr) 1997-09-05
ATE219365T1 (de) 2002-07-15
UA49004C2 (uk) 2002-09-16
EP0906101B1 (fr) 2002-06-19
BG102692A (en) 1999-04-30
CO4780020A1 (es) 1999-05-26
FR2745500B1 (fr) 1998-04-03
NO984035D0 (no) 1998-09-02
DE69713505D1 (de) 2002-07-25
DE69713505T2 (de) 2003-02-13
KR19990087387A (ko) 1999-12-27
IL126050A0 (en) 1999-05-09
JP2007182451A (ja) 2007-07-19
EE03511B1 (et) 2001-10-15
AR006082A1 (es) 1999-08-11
NO984035L (no) 1998-10-22
ZA971830B (en) 1997-09-04
HU227472B1 (en) 2011-07-28
NO315841B1 (no) 2003-11-03
SK282112B6 (sk) 2001-11-06
DK0906101T3 (da) 2002-10-14
SK121098A3 (en) 1999-01-11
HUP9902458A2 (hu) 2000-05-28
IL126050A (en) 2004-05-12
NZ331947A (en) 2000-03-27
ES2177942T3 (es) 2002-12-16
IN187739B (enEXAMPLES) 2002-06-15

Similar Documents

Publication Publication Date Title
US6099863A (en) Fast-dissolving galanthamine hydrobromide tablet
JP2007182451A (ja) ミゾラスチンを含有する徐放性医薬製剤
KR20120064141A (ko) 코팅된 정제 제형 및 방법
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA01004011A (es) Formulaciones farmaceuticas de liberacion controlada.
PL206069B1 (pl) Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę
WO2007049868A1 (en) Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
JP3576806B2 (ja) アンギオテンシン変換酵素阻害剤とカルシウムチャンネル拮抗剤との固定用量組合せ、製造法、および心血管病の治療におけるその用途
JP4945043B2 (ja) モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
HK1017999B (en) Slow-release pharmaceutical formulations containing mizolastin
US20050171119A1 (en) Pharmaceutical formulations with modified release
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물
JP3573287B2 (ja) 高吸収性固形製剤
CA2358395C (en) Extended release formulations of erythromycin derivatives
US20040192706A1 (en) Method and compositions for treating anxiety
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
HK1127564A (en) Oral controlled release formulation for sedative and hypnotic agents
HK1200107B (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SANOFI-SYNTHELABO

Free format text: FORMER NAME: SYNTHELABO

FGA Letters patent sealed or granted (standard patent)